bleomycin sulfate: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Fresenius Kabi Usa	BLEOMYCIN SULFATE	bleomycin sulfate	INJECTABLE;INJECTION	065185	ANDA	Fresenius Kabi USA, LLC	63323-136-10	1 VIAL in 1 CARTON (63323-136-10) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL	2009-02-13
Fresenius Kabi Usa	BLEOMYCIN SULFATE	bleomycin sulfate	INJECTABLE;INJECTION	065185	ANDA	Fresenius Kabi USA, LLC	63323-137-20	1 VIAL in 1 CARTON (63323-137-20) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL	2009-02-13
Hikma	BLEOMYCIN SULFATE	bleomycin sulfate	INJECTABLE;INJECTION	065042	ANDA	Hikma Pharmaceuticals USA Inc.	0143-9240-01	1 VIAL in 1 BOX, UNIT-DOSE (0143-9240-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL	2018-01-09
Hikma	BLEOMYCIN SULFATE	bleomycin sulfate	INJECTABLE;INJECTION	065042	ANDA	Hikma Pharmaceuticals USA Inc.	0143-9241-01	1 VIAL in 1 BOX, UNIT-DOSE (0143-9241-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL	2018-01-09
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

A comprehensive analysis of the global supply chain for bleomycin sulfate, a crucial chemotherapy agent, reveals concentrated manufacturing capabilities, significant patent expirations, and evolving regulatory landscapes impacting its availability and market dynamics. Key manufacturers are predominantly located in China and India, with limited independent production in other regions.

What is the Current Global Manufacturing Landscape for Bleomycin Sulfate?

The global manufacturing of bleomycin sulfate is concentrated among a small number of companies, primarily in Asia. China and India host the majority of active pharmaceutical ingredient (API) manufacturers. This concentration poses potential risks related to supply chain disruptions, geopolitical instability, and quality control.

Key Manufacturing Regions:
- China: Dominant supplier of bleomycin sulfate API. Several identified manufacturers have scaled production to meet global demand.
- India: Another significant producer of API, with a growing number of companies entering or expanding their presence in this market.
- Other Regions: Limited independent manufacturing exists in Europe and North America, often focusing on sterile finished dosage forms rather than raw API.
Top API Suppliers Identified:
- Companies like CSPC Pharmaceutical Group Limited (China) and various Indian API manufacturers are frequently cited as primary sources. Specific production volumes are proprietary but indicative of significant capacity.
Finished Dosage Form (FDF) Manufacturers:
- While API production is concentrated, FDF manufacturing is more geographically dispersed. This includes companies in the United States, Europe, and Japan, who import API for formulation.
Supply Chain Vulnerabilities:
- Geographic Concentration: Reliance on a few countries for API creates single-point-of-failure risks.
- Regulatory Hurdles: Changes in import/export regulations or manufacturing standards in key producing countries can impact supply.
- Logistics: Long transit times and complex cold chain requirements for certain formulations can add further risk.

Which Patents Cover Bleomycin Sulfate and When Do They Expire?

The original patents covering the discovery and initial synthesis of bleomycin have long expired. However, subsequent patents related to specific formulations, manufacturing processes, and polymorphic forms can still influence market exclusivity and generic entry.

Original Compound Patents:
- The foundational patents for bleomycin sulfate, primarily related to its discovery and basic chemical structure by Nippon Kayaku Co., Ltd., expired decades ago. The initial patents were filed in the late 1960s and early 1970s.
Formulation Patents:
- Patents focusing on improved stability, solubility, or specific delivery mechanisms for bleomycin sulfate may still be active or have recently expired. These can protect branded formulations from generic competition for a limited period.
- Example: Patents related to lyophilized bleomycin sulfate for enhanced shelf-life or specific reconstitution properties.
Process Patents:
- Patents covering novel or more efficient methods of synthesizing bleomycin sulfate API can provide a competitive advantage.
- These patents are often held by API manufacturers seeking to protect their proprietary production techniques.
Polymorphic Form Patents:
- Patents claiming specific crystalline forms (polymorphs) of bleomycin sulfate can impact bioequivalence and manufacturing consistency.
- The identification and patenting of new polymorphs can extend market exclusivity.
General Expiration Trends:
- The majority of bleomycin sulfate products are now off-patent, allowing for generic competition. However, the expiry of secondary patents related to specific manufacturing processes or advanced formulations can still create temporary market advantages for patent holders.
- A comprehensive review of patent databases (e.g., USPTO, EPO, WIPO) for specific bleomycin sulfate products and manufacturing processes is necessary to determine precise expiration dates for any active secondary patents. Without specific product identification, definitive expiry dates for all potential secondary patents cannot be provided.

What are the Regulatory Considerations for Bleomycin Sulfate?

The regulatory environment for bleomycin sulfate is complex, involving stringent quality controls and varying approval processes across different markets. Compliance with Good Manufacturing Practices (GMP) and pharmacopoeial standards is paramount.

Key Regulatory Bodies:
- U.S. Food and Drug Administration (FDA): Regulates bleomycin sulfate sold in the United States.
- European Medicines Agency (EMA): Oversees pharmaceutical products in the European Union.
- Pharmaceuticals and Medical Devices Agency (PMDA) Japan: Regulates products in Japan.
- National Medical Products Administration (NMPA) China: Oversees Chinese pharmaceutical regulations.
- Central Drugs Standard Control Organization (CDSCO) India: The national regulatory body for pharmaceuticals in India.
Pharmacopoeial Standards:
- United States Pharmacopeia (USP): Sets standards for bleomycin sulfate purity, potency, and testing methods in the US.
- European Pharmacopoeia (Ph. Eur.): Similar standards for the European market.
- Japanese Pharmacopoeia (JP): Standards for Japan.
- Manufacturers must adhere to the pharmacopoeial standards of the target markets.
Good Manufacturing Practices (GMP):
- All manufacturing facilities, both for API and finished drug products, must comply with current GMP guidelines.
- Regular inspections by regulatory authorities are conducted to ensure compliance.
- FDA, EMA, and other international bodies have harmonized GMP standards to some extent.
Drug Master Files (DMFs) / Active Substance Master Files (ASMFs):
- API manufacturers typically submit DMFs (US) or ASMFs (EU) to regulatory agencies. These confidential documents provide detailed information about the manufacturing process, quality control, and stability of the API.
- Finished drug product manufacturers reference these DMFs/ASMFs in their marketing authorization applications.
Biosimilar vs. Generic:
- Bleomycin sulfate is a small molecule drug, not a biologic. Therefore, generic versions, not biosimilars, are relevant. Generic manufacturers must demonstrate bioequivalence to the reference listed drug.
Supply Chain Audits:
- Pharmaceutical companies using bleomycin sulfate API often conduct their own audits of API suppliers to ensure quality and regulatory compliance beyond what is mandated by public agencies.

What are the Market Dynamics and Pricing Trends for Bleomycin Sulfate?

The market for bleomycin sulfate is characterized by a mature generic landscape, price sensitivity, and demand influenced by cancer treatment protocols and healthcare access.

Market Size:
- The global bleomycin sulfate market size is difficult to pinpoint with exact public figures due to the generic nature of the product and fragmented reporting. However, it is a multi-million dollar market globally, driven by its established role in treating various cancers.
Pricing Factors:
- Generic Competition: The presence of multiple generic manufacturers, particularly from China and India, has led to significant price competition.
- API Costs: Fluctuations in the cost of raw materials and manufacturing in key API-producing regions directly impact pricing.
- Formulation Complexity: Lyophilized sterile powder formulations, which require specialized manufacturing and packaging, typically command higher prices than simpler formulations.
- Tender Processes: In many countries, bleomycin sulfate is procured through government tenders, which often drive prices down through competitive bidding.
- Geographic Market Variations: Prices vary significantly between developed and developing markets due to differences in regulatory requirements, market access, and reimbursement policies.
Demand Drivers:
- Cancer Incidence: The prevalence of cancers treated with bleomycin (e.g., Hodgkin lymphoma, non-Hodgkin lymphoma, testicular cancer, squamous cell carcinoma) is the primary demand driver.
- Treatment Protocols: Established oncology treatment regimens that include bleomycin sulfate contribute to consistent demand.
- Healthcare Access: Expansion of healthcare access in emerging markets can increase demand for essential chemotherapies like bleomycin sulfate.
- Competition from Newer Therapies: While bleomycin sulfate remains a standard of care for certain indications, the development of newer targeted therapies or immunotherapies could, in the long term, influence its use and demand.
Competitive Landscape:
- The market is highly fragmented with numerous generic manufacturers and distributors.
- Key players often compete on price, supply reliability, and quality certifications (e.g., FDA, EMA approval of their manufacturing sites).

What are the Key Challenges and Opportunities in the Bleomycin Sulfate Supply Chain?

Navigating the bleomycin sulfate market presents distinct challenges related to supply assurance and quality, alongside opportunities for optimization and strategic sourcing.

Challenges:
- Supply Chain Volatility: Reliance on a limited number of API manufacturers in specific geographic regions creates vulnerability to geopolitical events, natural disasters, or regulatory changes.
- Quality Assurance: Ensuring consistent API quality and compliance with international GMP standards across all suppliers is critical and requires rigorous auditing.
- Counterfeit Products: The risk of counterfeit or substandard bleomycin sulfate entering the supply chain is a persistent concern in the generic drug market, especially for products sourced from less regulated channels.
- Logistical Complexity: Maintaining the integrity of bleomycin sulfate, particularly lyophilized forms, throughout the cold chain from manufacturing to patient administration requires robust logistics.
- Price Pressures: Intense competition among generic suppliers can lead to thin profit margins for manufacturers and distributors.
Opportunities:
- Diversification of Supply: Strategic partnerships with multiple API suppliers in different geographic locations can mitigate supply risks.
- Vertical Integration: Companies that control both API manufacturing and finished drug product formulation may achieve greater cost efficiencies and supply chain control.
- Technological Advancements: Innovations in manufacturing processes for bleomycin sulfate API could lead to improved yields, reduced costs, and enhanced environmental sustainability.
- Data Analytics for Demand Forecasting: Implementing advanced data analytics can improve demand forecasting, optimizing inventory management and reducing waste.
- Strategic Sourcing: Pharmaceutical companies can leverage their purchasing power and conduct thorough due diligence to secure reliable, high-quality bleomycin sulfate at competitive prices.
- Emerging Market Access: Expanding access to bleomycin sulfate in underserved regions presents a growth opportunity, provided pricing and distribution challenges are addressed.

Key Takeaways

Bleomycin sulfate manufacturing is concentrated in China and India, creating supply chain vulnerabilities.
Original patents have expired, but secondary patents on formulations or processes may still exist.
Stringent regulatory oversight by bodies like the FDA and EMA, coupled with adherence to pharmacopoeial standards and GMP, is essential.
The market is characterized by intense generic competition, price sensitivity, and demand driven by cancer treatment protocols.
Key challenges include supply volatility and quality assurance, while opportunities lie in supply diversification and technological advancements.

Frequently Asked Questions

Are there any active patents on the bleomycin sulfate molecule itself that prevent generic production? No, the original compound patents for bleomycin sulfate have expired, allowing for generic manufacturing.
What is the typical shelf-life of a bleomycin sulfate vial? The shelf-life for lyophilized bleomycin sulfate typically ranges from 24 to 36 months when stored under recommended conditions, usually at controlled room temperature or refrigerated, protected from light. Specific product labeling and manufacturer data should be consulted.
What are the main indications for which bleomycin sulfate is prescribed? Bleomycin sulfate is primarily used in the treatment of various cancers, including Hodgkin lymphoma, non-Hodgkin lymphoma, testicular cancer, squamous cell carcinomas (e.g., of the head and neck, cervix, vulva), and malignant pleural effusions.
Can bleomycin sulfate be manufactured in facilities that do not have FDA approval? While API can be manufactured in countries without direct FDA approval of the API facility, finished bleomycin sulfate products intended for the U.S. market must be manufactured in FDA-approved facilities, and the API used must be sourced from suppliers whose Drug Master Files (DMFs) are accepted by the FDA. Similar requirements apply for other major markets with their respective regulatory agencies.
How does the cost of bleomycin sulfate API compare between Chinese and Indian manufacturers? Pricing is highly competitive and subject to market conditions, production volumes, and contractual agreements. Generally, both Chinese and Indian manufacturers offer competitive pricing, with variations depending on the supplier's scale, quality certifications, and specific production costs. Precise comparative pricing data is proprietary and fluctuates regularly.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA official website] [2] European Medicines Agency. (n.d.). Active Substance Master Files (ASMFs). Retrieved from [EMA official website] [3] United States Pharmacopeia. (n.d.). Bleomycin Sulfate. Retrieved from [USP official website] [4] European Pharmacopoeia. (n.d.). Bleomycin Sulfate. Retrieved from [Ph. Eur. official website] [5] Nippon Kayaku Co., Ltd. (Various historical patent filings and corporate disclosures). (Specific patent numbers and dates vary). [6] Industry market research reports on oncology drugs and API manufacturing (proprietary data sources).

Suppliers and packagers for generic pharmaceutical drug: bleomycin sulfate